Practice question

Answer the question and get instant feedback.

Moderate"SGLT2 inhibitors are a foundational class improving HF outcomes. Ivabradine is indicated when HR ≥70 in sinus rhythm. Vericiguat benefits high‑risk patients after recent decompensation. CCBs/NSAIDs are harmful/ineffective in HFrEF."Cardiology"moderate"

A 63-year-old with HFrEF (EF 35%) on ARNI, beta-blocker, and MRA has persistent symptoms. Which additional therapy improves outcomes per 2022 HF guideline?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.